Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 1
2018 1
2019 5
2020 6
2021 5
2022 2
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma.
Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Nevala WK, Walters DK, Parikh SA, Lin Y, Jelinek DF, Kay NE, Bergsagel PL, Kenderian SS. Sakemura R, et al. Among authors: bezerra ed. Blood. 2022 Jun 30;139(26):3708-3721. doi: 10.1182/blood.2021012811. Blood. 2022. PMID: 35090171 Free article.
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.
Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, Sorror ML, Turtle CJ, Maloney DG, Bar M. Cordeiro A, et al. Among authors: bezerra ed. Biol Blood Marrow Transplant. 2020 Jan;26(1):26-33. doi: 10.1016/j.bbmt.2019.08.003. Epub 2019 Aug 13. Biol Blood Marrow Transplant. 2020. PMID: 31419568 Free PMC article. Clinical Trial.
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Jamieson AW, Bar M, Cassaday RD, Chapuis AG, Cowan AJ, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. Gauthier J, et al. Among authors: bezerra ed. Blood. 2021 Jan 21;137(3):323-335. doi: 10.1182/blood.2020006770. Blood. 2021. PMID: 32967009 Free PMC article. Clinical Trial.
AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.
Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS. Sakemura RL, et al. Among authors: bezerra ed. Cancer Immunol Res. 2023 Sep 1;11(9):1222-1236. doi: 10.1158/2326-6066.CIR-22-0254. Cancer Immunol Res. 2023. PMID: 37378662 Free PMC article.
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Sakemura RL, Manriquez Roman C, Horvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo EJ, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Hefazi M, Ruff MW, Kimball BL, Mai LK, Huynh TN, Nevala WK, Ilieva K, Augsberger C, Patra-Kneuer M, Schanzer J, Endell J, Heitmüller C, Steidl S, Parikh SA, Ding W, Kay NE, Nowakowski GS, Kenderian SS. Sakemura RL, et al. Among authors: bezerra ed. Blood. 2024 Jan 18;143(3):258-271. doi: 10.1182/blood.2022018905. Blood. 2024. PMID: 37879074 Free PMC article.
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Wiedmeier-Nutor JE, et al. Among authors: bezerra ed. Clin Lymphoma Myeloma Leuk. 2023 Jun;23(6):456-462. doi: 10.1016/j.clml.2023.03.002. Epub 2023 Mar 7. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37003846 Free PMC article.
Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents.
Johnson IM, Bezerra ED, Farrukh F, McCullough K, Al-Kali A, Alkhateeb HB, Begna K, Litzow MR, Hogan WJ, Shah MV, Patnaik MM, Tefferi A, Gangat N. Johnson IM, et al. Among authors: bezerra ed. Blood Adv. 2022 Sep 13;6(17):5227-5231. doi: 10.1182/bloodadvances.2022007333. Blood Adv. 2022. PMID: 35358999 Free PMC article. No abstract available.
Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy.
Saliba AN, Xie Z, Higgins AS, Andrade-Gonzalez XA, Fuentes-Bayne HE, Hampel PJ, Kankeu Fonkoua LA, Childs DS, Rakshit S, Bezerra ED, Kommalapati A, Lou Y, Rivera CE, Price KA, Chintakuntlawar A, Yan Y, Schwecke AJ, Block MS, Thanarajasingam U, Thanarajasingam G, Wolanskyj-Spinner AP, Marshall AL, Kottschade LA, Go RS, Al-Kali A. Saliba AN, et al. Among authors: bezerra ed. Am J Hematol. 2021 Oct 1;96(10):E362-E367. doi: 10.1002/ajh.26273. Epub 2021 Jul 2. Am J Hematol. 2021. PMID: 34137072 Free article. No abstract available.
Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy.
Bezerra ED, Iqbal M, Munoz J, Khurana A, Wang Y, Maurer MJ, Bansal R, Hathcock MA, Bennani N, Murthy HS, Rosenthal AC, Paludo J, Villasboas JC, Johnston PB, Habermann TM, Ansell SM, Castro JE, Witzig TE, Kharfan-Dabaja MA, Nowakowski GS, Lin Y. Bezerra ED, et al. Blood Adv. 2023 Apr 25;7(8):1572-1576. doi: 10.1182/bloodadvances.2022007868. Blood Adv. 2023. PMID: 36219588 Free PMC article. No abstract available.
24 results